Evidence map›Paper›PMID 19401777›Full record

ArticlePloS one2009

Both strands of siRNA have potential to guide posttranscriptional gene silencing in mammalian cells.

Jun-Xia Wei, Jie Yang, Ji-Feng Sun, Lin-Tao Jia, Yong Zhang, Hui-Zhong Zhang, Xia Li, Yan-Ling Meng, Li-Bo Yao, An-Gang Yang

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Transcriptional gene silencing in humans.Nucleic acids research · 2016
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Modified siRNA structure with a single nucleotide bulge overcomes conventional siRNA-mediated off-target silencing.Molecular therapy : the journal of the American Society of Gene Therapy · 2011
    Article
  16. Review
  17. Article
  18. Article
  19. What are natural antisense transcripts good for?Biochemical Society transactions · 2010
    Review
  20. Novel RNA-based strategies for therapeutic gene silencing.Molecular therapy : the journal of the American Society of Gene Therapy · 2010
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Jun-Xia WeiState Key Laboratory of Cancer Biology; Department of Biochemistry and Molecular Biology, Fourth Military Medical University, Xi'an, China.
Jie Yang
Ji-Feng Sun
Lin-Tao Jia
Yong Zhang
Hui-Zhong Zhang
Xia Li
Yan-Ling Meng
Li-Bo Yao
An-Gang Yang
Air Force Medical University · CNState Key Laboratory of Cancer Biology

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the widespread application of RNA interference (RNAi) as a research tool for diverse purposes, the key step of strand selection of siRNAs during the formation of RNA-induced silencing complex (RISC) remains poorly understood. Here, using siRNAs targeted to the complementary region of Survivin and the effector protease receptor 1 (EPR-1), we show that both strands of the siRNA duplex can find their target mRNA and are equally eligible for assembly into Argonaute 2 (Ago2) of RISC in HEK293 cells. Transfection of the synthetic siRNA duplexes with different thermodynamic profiles or short hairpin RNA (shRNA) vectors that generate double-stranded RNAs (dsRNAs), permitting processing specifically from either the 5' or 3' end of the incipient siRNA, results in the degradation of the respective target mRNAs of either strand of the siRNA duplex with comparable efficiencies. Thus, while most RNAi reactions may follow the thermodynamic asymmetry rule in strand selection, our study suggests an exceptional mode for certain siRNAs in which both strands of the duplex are competent in sponsoring RNAi, and implies additional factors that might dictate the RNAi targets.

Indexed as

RNA InterferenceArgonaute ProteinsBase SequenceCarboxypeptidasesCell LineCytidineDNA PrimersEukaryotic Initiation Factor-2HumansInhibitor of Apoptosis ProteinsMicrotubule-Associated ProteinsReceptors, Cell SurfaceRibonuclease IIIRNA, ComplementaryRNA, MessengerRNA Processing, Post-TranscriptionalAGO2 protein, humanArgonaute ProteinsBIRC5 protein, humanCarboxypeptidasesCytidineDNA PrimersEukaryotic Initiation Factor-2Inhibitor of Apoptosis ProteinsMicrotubule-Associated ProteinsReceptors, Cell SurfaceRibonuclease IIIRNA, ComplementaryRNA, MessengerRNA, Small InterferingSCPEP1 protein, humanSurvivinUridine

Identifiers

PMID19401777
PMCPMC2671169
OpenAlexW2038396556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.